Inhibition of aldose reductase activity by Cannabis sativa chemotypes extracts with high content of cannabidiol or cannabigerol.

摘要: Aldose reductase (ALR2) is a key enzyme involved in diabetic complications and the search for new aldose inhibitors (ARIs) currently very important. The synthetic ARIs are often associated with deleterious side effects medicinal edible plants, containing compounds inhibitory activity, could be useful prevention therapy of complications. Non-psychotropic phytocannabinoids exert multiple pharmacological therapeutic potential many diseases such as inflammation, cancer, diabetes. Here, we have investigated extracts their fractions from two Cannabis sativa L. chemotypes high content cannabidiol (CBD)/cannabidiolic acid (CBDA) cannabigerol (CBG)/cannabigerolic (CBGA), respectively, on human recombinant pig kidney activity vitro. A molecular docking study was performed to evaluate interaction these cannabinoids active site ALR2 compared known ARIs. showed significant dose-dependent (>70%) higher than fractions. greater acidic cannabinoid-rich Comparative results shown stability ALR2-cannabinoid acids complex other inhibitors. non-psychotropic CBD/CBDA or CBG/CBGA significantly inhibit activity. These may some relevance possible use C. based preparations